A recent American study has discovered a biomarker in the brain tissue of people with Alzheimer’s. Help in the initial stage of the disease.
A blood test appears to be enough to anticipate Alzheimer ‘s and diagnose the neurodegenerative disease before it is more severe. There are 50 million people with dementia in the world. A study from North Carolina Central University appears to have discovered a new biomarker . They are molecules, proteins or other biological substances associated with various pathologies. They are used to detect and more accurately predict diseases such as Alzheimer’s in people who are still alive. Among the biomarkers used in the diagnosis of Alzheimer’s disease, the main ones are tau protein tangles . They are located in two specific sites called p-tau181 and p-tau217.
By comparing the brain tissue of Alzheimer’s patients with that of healthy people, American researchers went on to hunt down other p-tau biomarkers. These are capable of diagnosing Alzheimer’s in its early stages. Specifically, it is a tau tangle named p-tau198 which recognizes Alzheimer’s from other neurodegenerative diseases with tau tangles. A way to understand the difference between brain tissue of patients with mild cognitive impairment due to the disease and those who are not affected.
Both p-tau217, discovered by other research groups, and the new biomarker p-tau198 that we discovered have shown promise for early disease detection in our studies. A slowly progressing disease like Alzheimer’s offers a long window of opportunity for medical intervention if we can detect changes early.
Experts deduce that the study increases knowledge of the characteristics of the molecules and the localization of proteins involved in Alzheimer’s. One day such a study could be useful in understanding what problems are having in the brain before they do more damage.
- Alzheimer’s: a blood test to find it in advance and try to contain the neurological damage (ohga.it)